| Primary |
| Factor Viii Deficiency |
44.9% |
| Haemorrhage Prophylaxis |
18.4% |
| Drug Use For Unknown Indication |
16.3% |
| Haemophilia |
6.1% |
| Rhinoplasty |
6.1% |
| Haemarthrosis |
4.1% |
| Haemorrhage |
2.0% |
| Prophylaxis |
2.0% |
|
| Factor Viii Inhibition |
36.4% |
| Lung Squamous Cell Carcinoma Stage Unspecified |
12.1% |
| Haemorrhage |
9.1% |
| Anti Factor Viii Antibody Positive |
6.1% |
| Urticaria |
6.1% |
| Death |
3.0% |
| Haematoma |
3.0% |
| Hyperhidrosis |
3.0% |
| Inhibiting Antibodies |
3.0% |
| Injection Site Extravasation |
3.0% |
| Pyrexia |
3.0% |
| Rash |
3.0% |
| Respiratory Distress |
3.0% |
| Subcutaneous Haematoma |
3.0% |
| Tachycardia |
3.0% |
|
| Secondary |
| Factor Viii Deficiency |
54.0% |
| Haemorrhage Prophylaxis |
23.6% |
| Drug Use For Unknown Indication |
5.2% |
| Factor Viii Inhibition |
3.2% |
| Haemarthrosis |
3.2% |
| Immune System Disorder |
3.2% |
| Haemophilia |
2.8% |
| Haemorrhage |
2.4% |
| Prophylaxis |
2.4% |
|
| Factor Viii Inhibition |
44.7% |
| Injection Site Extravasation |
11.8% |
| Haematoma |
11.2% |
| Haemorrhage |
6.8% |
| Anti Factor Viii Antibody Positive |
5.0% |
| Urticaria |
5.0% |
| Venous Thrombosis Limb |
5.0% |
| Inhibiting Antibodies |
3.7% |
| Hyperhidrosis |
1.9% |
| Rash |
1.9% |
| Pyrexia |
1.2% |
| Respiratory Distress |
1.2% |
| Tachycardia |
0.6% |
|
| Concomitant |
| Rheumatoid Arthritis |
50.0% |
| Attention Deficit/hyperactivity Disorder |
25.0% |
| Epilepsy |
25.0% |
|
| Hepatocellular Damage |
33.3% |
| Rash Generalised |
33.3% |
| Vertigo |
33.3% |
|
